UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~March~~December 1524, 2010
Date of Report (Date of earliest event reported)

MIV THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation) 000-30453 (Commission File Number) 01-0809204 (IRS Employer Identification No.)

Nevada	000-30453	01-0809204
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o 1500-1055 West Georgia Street, Vancouver, British Columbia, Canada (Address of principal executive offices) V6E 4N7 (Zip Code)

1-8765 Ash Street, Vancouver, British Columbia, Canada		V6P 6T3
(Address of principal executive offices)		(Zip Code)

(604) 808-6128

Registrant's telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~SECTION 1 - REGISTRANT'S BUSINESS AND OPERATIONS~~__________

~~Item~~SECTION ~~1.01 Entry~~8 ~~into~~- aOTHER ~~Material Definitive Agreement.~~EVENTS

~~Innomed~~Item ~~Agreement~~8.01 Other Events.

~~Effective~~On ~~October~~December 1224, 2010, MIV Therapeutics, Inc. (the "~~MIV~~Company"), ~~through~~issued ~~its~~a ~~wholly~~news ~~owned~~release ~~subsidiary,~~announcing ~~MIV~~that ~~Scientific~~it ~~Holdings~~is ~~Ltd.~~that ~~("MIV~~it ~~Scientific"),~~is ~~entered~~nearing ~~into~~the acompletion ~~Share~~of ~~Purchase~~an ~~Agreement~~agreement ~~(the~~regarding ~~"Innomed~~restructuring ~~Agreement")~~activities with ~~Innomed~~a ~~Scientific~~large ~~Limited~~medical ~~("Innomed")~~investment ~~and~~group Hybased Tyin ~~Tiefung.~~Asia to provide significant further funding to the Company.

~~Pursuant~~The toshare ~~the~~purchase ~~terms~~agreements ofthat the Company entered into with CCT Tech International Limited ("CCT") and Innomed ~~Agreement~~Scientific Limited ("Innomed"), ~~MIV~~which ~~Scientific~~the ~~will~~Company ~~purchase~~announced ~~all~~in ofNovember, are being postponed so that the ~~issued~~Company ~~and~~can ~~outstanding~~better ~~shares~~restructure the transaction, which senior management of ~~Innomed~~the (Company believes will result in a broader positive impact for the ~~"Innomed~~Company ~~Shares")~~and its shareholders. The ~~purchase~~original ~~price~~agreements ~~for~~with ~~the~~CCT and Innomed ~~Shares~~were terminated according to Hong Kong securities commission listing rules because a new deal constitutes a material change. Senior management of the Company is: in the final stage of completing definitive agreements with the new party.

~~US$5~~In ~~million~~addition, inthe ~~cash~~Company (recently signed a Memorandum of Understanding with a Chinese distributor to provide the ~~"Innomed~~distributor ~~Cash~~with ~~Consideration");~~exclusive distribution rights for the Company's products for the major cities and provinces of China.

~~US$15 million to be paid as 650,000,000 non-voting redeemable convertible preference shares of CCT Tech International Limited ("CCT") (the "Innomed Non-Cash Consideration").~~__________

~~A copy of the Innomed Agreement is attached to this Current Report on Form 8~~-K as2 ~~Exhibit 10.1.~~-

Share Purchase Agreement
Effective October 13, 2010, the Board of Directors of MIV ratified the entering into of a Share Purchase and Subscription Agreement (the "Share Purchase Agreement") pursuant to which MIV has agreed to sell to CCT all of the issued and outstanding shares (the "Purchased Shares") of its wholly owned subsidiary, MIV Scientific, on or before the Completion Date, as such term is defined in the Share Purchase Agreement (which is expected to be on or around December 15, 2010, unless otherwise agreed by the parties).
Pursuant to the terms of the Share Purchase Agreement, the purchase price for the Purchased Shares is U$100 million payable as follows:
US$20 million payable by CCT in cash (the "Subscription Consideration"); and
US$80 million payable by CCT allotting and issuing 3,466,700,000 non-voting redeemable convertible preference shares ("Redeemable CPS") of CCT (the "Purchase Consideration").
Pursuant to the terms of the Share Purchase Agreement, the Subscription Consideration will be paid as follows:
a refundable US$1 million deposit within 3 business days of the date of the Share Purchase Agreement (the "Deposit");
US$11 million within 3 business days of the Completion Date (the "Second Payment"); and
US$8 million within 1 year of the Completion Date (the "Third Payment").
In accordance with the terms of the Share Purchase Agreement, MIV will use the Subscription Consideration as follows:
the Deposit shall be used as payment of the deposit for the Innomed Cash Consideration;
US$ 4 million of the Second Payment shall be used for satisfying the balance of the Innomed Cash Consideration;
up to US$ 3 million of the Second Payment shall be used as reimbursement of costs and expenses incurred and paid by MIV for obtaining a CE Mark in the European Union;
the balance of the Second Payment as working capital for two Shanghai companies related to Innomed;
US$ 5 million of the Third Payment shall be used for the purposes of (i) human trial of, and (ii) obtaining approvals of the State Food and Drug Administration ("SFDA") of the People's Republic of China ("PRC") and other relevant Governmental Authorities on, the 4th generation of Nonpolymeric Drug-Eluting Stents (the "Product") in the PRC; and
the balance of the Third Payment as working capital of the MIV, Innomed and the two Shanghai companies (the "Group") or to be used in such other manner as CCT and certain key management of MIV, CCT and Innomed may agree.
In accordance with the terms of the Share Purchase Agreement, the Consideration Shares will be
allotted and issued by CCT and credited as fully paid at the issue price of HK$0.18 each as follows:
650,000,000 Redeemable CPS shall be allotted and issued to Innomed Scientific Limited as provided in the Innomed Agreement to satisfy the Innomed Non-cash Consideration;
390,010,000 Redeemable CPS shall be allotted and issued to MIV on the fifth Business Day following the day on which MIV provides evidence reasonably satisfactory to CCT that CE Mark for the Product for the European Union has been obtained by MIV Scientific, which is expected to happen within 12 months of Completion;
1,040,010,000 Redeemable CPS shall be allotted and issued to MIV on the fifth Business Day following the day on which MIV provides evidence reasonably satisfactory to CCT that the SFDA has granted approval for the marketing and sale of the Product in the PRC, which is expected to happen within 24 months of Completion; and
1,386,680,000 Redeemable CPS shall be allotted and issued to MIV on the fifth Business Day following the day on which the audited annual consolidated financial statements of the Group prepared in accordance with HK GAAP, audited by the auditors of CCT, for any financial year ending on or before December 31, 2012 are delivered to CCT and such accounts show that the audited Consolidated Net Profit After Tax of the Group for any of such financial year is at least HK$70 million.
A copy of the Share Purchase Agreement is attached to this Current Report on Form 8-K as Exhibit 10.2.
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective on March 15, 2010, the Board of Directors of MIV Therapeutics, Inc. (the "Company") accepted Alan Lindsay's resignation as Chairman and as a Director and accepted the consent to act of Chris Chen to serve as Chairman and a Director of the Company.
Mr. Chris Chen worked as a strategic advisor for MIV since 2005 and has been assisting in navigating our Company through his involvement in strategic planning, financing, marketing, product development, and establishing networks with R&D strategic partners. Mr. Chen was also a director of LeoFibo Holdings Inc., a specialized consulting firm offering financial advisory services, and has extensive experience in investing in companies in different sectors from pre-revenue to sizable public companies. Mr. Chen also has 15 years experience in capital markets as a director and president of several public companies in different jurisdictions including Canada, the U.S. and the United Kingdom.
As a consequence of the above resignation and appointment, the Company's Board of Directors and Executive Officers are now comprised of the following:
Name Position Chris Chen Chairman and a director Patrick A. McGowan President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and a director
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01      Financial Statements and Exhibits
(a)     Financial Statements of Business Acquired
Not applicable.
(b)     Pro forma Financial Information
Not applicable.
(c)     Shell Company Transaction
Not applicable.
(d)     Exhibits
Exhibit Description
10.1 Share Purchase Agreement dated October 12, 2010 between Innomed Scientific Limited, Hu Ty Tiefung and MIV Scientific Holdings Ltd.
10.2 Share Purchase and Subscription Agreement dated October 13, 2010 between MIV Therapeutics Inc., CCT International Limited and MIV Scientific Holdings Ltd.
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MIV THERAPEUTICS, INC. DATE: ~~November~~January 245, ~~2010~~2011. By: "/s/ Patrick A. McGowan" Name: Patrick A. McGowan Title: President, Chief Executive Officer, ~~Treasurer,~~ Chief Financial Officer, Secretary, Treasurer and a director

__________

- 3 -

Exhibit	Description
10.1	Share Purchase Agreement dated October 12, 2010 between Innomed Scientific Limited, Hu Ty Tiefung and MIV Scientific Holdings Ltd.
10.2	Share Purchase and Subscription Agreement dated October 13, 2010 between MIV Therapeutics Inc., CCT International Limited and MIV Scientific Holdings Ltd.

Filing Compare · MIV THERAPEUTICS INC